PeRiopEratiVE SmokiNg CessaTion Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,720

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

January 1, 2027

Conditions
Smoking (Tobacco) AddictionSmoking Cessation
Interventions
DRUG

Cytisine

Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation

BEHAVIORAL

Video Messaging

Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.

Trial Locations (4)

L8L 2X2

Hamilton General Hospital, Hamilton

L8V 5C2

Juravinski Cancer Centre, Hamilton

K7L 3N6

Kingston Health Science Centre with its research institute Kingston General Health Research Institute, Kingston

N6C 2R5

Lawson Health Research Institute: London Health Sciences Centre Research Inc. and the Lawson Research Institute, London

All Listed Sponsors
lead

Population Health Research Institute

OTHER

NCT05102123 - PeRiopEratiVE SmokiNg CessaTion Trial | Biotech Hunter | Biotech Hunter